Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Download in electronic PDF format for $75
Abstract: Primary focal hyperhidrosis is idiopathic, localized, uncontrollable, excessive, and unpredictable sweating beyond what is necessary to regulate body temperature. Primary hyperhidrosis is thought to affect approximately 2% to 3% of the population, and its effect on a patient's quality of life is very significant. Primary focal hyperhidrosis can be managed using various therapeutic options, including drugs (topical and systemic), nonsurgical interventions (e.g., iontophoresis, botulinum toxin injections), and surgery. This article, which is presented in 2 parts, is a comprehensive review of the topical, evidence-based treatments of primary focal hyperhidrosis, and it covers the following active pharmaceutical ingredients: aluminum salts, methenamine, glycopyrronium salts, oxybutynin chloride; the latter 2 ingredients will be discussed in part 2 of this article. This article discusses the evidence-based data that exists from clinical trials that support the use of topical medications to treat the pathology from efficacy and from a safety point of view. This review also discusses compounding considerations for professionally and safely compounding various topical preparations. In addition, a range of relevant formulas are attached to the article and can be used by compounding pharmacists.
Related Keywords:
Eyal Zur, BSc Pharm, RPh, MBA, excessive sweating, perspiration, exocrine sweat glands, patient quality of life, anticholinergic agents, iontophoresis, topical preparations, formulations, antiperspirants, aluminum salts, drug safety, aluminum chloride hexahydrate, salicylic acid, contact dermatitis, methenamine hippurate, deodorants
Related Categories:
DERMATOLOGY, FORMULATIONS, ADVERSE DRUG EVENTS, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
|
Jan/Feb 2019
Pg. 23-31
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
|
Mar/Apr 2019
Pg. 94-104
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
|
Nov/Dec 2011
Pg. 458-463
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
|
Nov/Dec 2012
Pg. 462-469
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
|
Jul/Aug 2019
Pg. 288-293
|
Erratum: Zur E. Topical Treatment of Primary Focal Hyperhidrosis, Part 2. IJPC 2019; 23(2):94-104.
|
Jul/Aug 2019
Pg. 351
|
Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications
Agbi Kelechi E, Carvalho Maria, Phan Ha, Tuma Cristiane
|
Jan/Feb 2017
Pg. 22-27
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
|
May/Jun 2019
Pg. 200-207
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
|
Sep/Oct 2019
Pg. 366-375
|
Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
|
Jan/Feb 2014
Pg. 14-19
|
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
|
Nov/Dec 2018
Pg. 446-454
|
Basics of Compounding for Iontophoresis, Part II
Allen Loyd V Jr
|
Jul/Aug 2002
Pg. 288-292
|
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Nov/Dec 2020
Pg. 482-490
|
A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Riepl Mike
|
Jul/Aug 2022
Pg. 270-274
|
Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Jones Nat, Carvalho Maria, Branvold-Herr Andrea
|
May/Jun 2017
Pg. 205-211
|
Topical Therapy for Localized Hyperhidrosis
Glasnapp Andrew
|
Jan/Feb 2001
Pg. 28-29
|
Return to Top |